Surmodics (NASDAQ: SRDX) is one of 82 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its rivals? We will compare Surmodics to related companies based on the strength of its profitability, dividends, valuation, risk, earnings, institutional ownership and analyst recommendations.
Volatility and Risk
Surmodics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Surmodics’ rivals have a beta of 0.95, meaning that their average stock price is 5% less volatile than the S&P 500.
Earnings and Valuation
This table compares Surmodics and its rivals gross revenue, earnings per share and valuation.
Surmodics’ rivals have higher revenue and earnings than Surmodics. Surmodics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Surmodics and its rivals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a summary of recent ratings and target prices for Surmodics and its rivals, as reported by MarketBeat.com.
||Strong Buy Ratings
Surmodics presently has a consensus price target of $40.00, indicating a potential upside of 31.36%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 6.86%. Given Surmodics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Surmodics is more favorable than its rivals.
Institutional & Insider Ownership
84.5% of Surmodics shares are owned by institutional investors. Comparatively, 65.6% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 6.4% of Surmodics shares are owned by company insiders. Comparatively, 12.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Surmodics beats its rivals on 7 of the 13 factors compared.
Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company’s In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.
Receive News & Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.